Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type

doi:10.1016/0006-3223(89)90145-5

Biological Psychiatry

Volume 25, Issue 1, 1 January 1989, Pages 39-48

https://doi.org/10.1016/0006-3223(89)90145-5 Get rights and content

Abstract

Delusions, misidentifications and hallucinations occur frequently throughout the course of senile dementia of the Alzheimer type (SDAT). Rates of psychosis among subjects with moderate to severe SDAT range from 42% to 84% in our study group; at least half of persons with SDAT with no prior psychiatric history will display psychosis at some point during the course of dementia. Furthermore, psychotic symptoms are associated with accelerated cognitive deterioration, but not with increased mortality.

References (34)

JL Cummings
Organic psychoses: Delusional disorders and secondary mania
Psychiatr Clin North Am
(1986)
A Alzheimer
About a peculiar disease of the cerebral cortex
Alz Dis Assoc Dis Orders
(1987)
American Psychiatric Association
H Arai et al.
Changes of biogenic amines and their metabolites in post-mortem brains from patients with Alzheimer-type dementia
J Neurochem
(1984)
L Berg
Clinical Dementia Rating
Br J Psychiatry
(1984)
L Berg et al.
Mild senile dementia of Alzheimer type: Research Diagnostic Criteria recruitment and description of a study population
J Neurol Neurosurg Psychiatry
(1982)
L Berg et al.
Mild senile dementia of the Alzheimer type
Longitudinal assessment
(1987)
G Blessed et al.
The association between quantitative measures of dementia and of senile change in the cerebral gray matter of elderly subjects
Br J Psychiatry
(1968)
W Bondareff et al.
Loss of neurons of origin of adrenergic projection of cerebral cortex (nucleus locus ceruleus) in senile dementia
Neurology
(1982)
WJ Burke et al.
Symptoms of depression in senile dementia of the Alzheimer type
Alz Dis Assoc Dis
(1988)

A Cross et al.

Serotonin receptor changes in dementia of the Alzheimer type

J Neurochem

(1984)

JL Cummings et al.

Neuropsychiatrie aspects of multi-infarct dementia and dementia of the Alzheimer type

Arch Neurol

(1987)

P Davies et al.

Recent advances in the neurochemistry of Alzheimer's disease

J Clin Psychiatry

(1987)

S Dekosky et al.

Laminar organization of cholinergic circuits in human frontal cortex in Alzheimer's disease and aging

Neurology

(1985)

WC Drevets et al.

Erotomania and senile dementia of the Alzheimer type

Br J Psychiatry

(1987)

P Francis et al.

Neurochemical studies of early-onset Alzheimer's disease

N Engl J Med

(1985)

L Goodman

Alzheimer's disease. A clinical-pathologic analysis of 23 cases with a theory on pathogenesis

J Nerv Ment Dis

(1953)

Cited by (291)

Overview of Alzheimer’s and Parkinson’s diseases and the role of protein aggregation in these neurodegenerative diseases
2020, Handbook of Innovations in Central Nervous System Regenerative Medicine
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most common neurodegenerative diseases, and together they affect approximately 56 million people worldwide. Despite distinct clinical features and the involvement of relatively disparate neural systems, both diseases are proteinopathies with significant overlap in some of the potential mechanisms of neuronal dysfunction and death. Models of protein aggregation and the relationship to disease onset and progression have widespread implications. Clearly, understanding the role protein aggregation plays in supporting or damaging cellular function is key to understanding the mechanisms of disease and developing new, effective therapies. A second application of this knowledge is to the development of relevant biomarkers of disease. Together, early identification of disease onset and the targeting of appropriate cellular pathways or polypeptides provide the best opportunity to develop disease-modifying interventions for people with neurodegenerative diseases. This chapter provides an overview of AD and PD, and it discusses current theories of the relationship between protein aggregation and neurodegeneration.
Psychosis in Alzheimer's disease
2014, Biological Psychiatry
Psychotic symptoms, delusions and hallucinations, occur in approximately 50% of individuals with Alzheimer’s disease (AD) (AD with psychosis [AD + P]). Pharmacotherapies for AD + P have limited efficacy and can increase short-term mortality. These observations have motivated efforts to identify the underlying biology of AD + P. Psychosis in AD indicates a more severe phenotype, with more rapid cognitive decline beginning even before psychosis onset. Neuroimaging studies suggest that AD + P subjects demonstrate greater cortical synaptic impairments than AD subjects without psychosis, reflected in reduced gray matter volume, reduced regional blood flow, and reduced regional glucose metabolism. Neuroimaging and available postmortem evidence further indicate that the impairments in AD + P, relative to AD subjects without psychosis, are localized to neocortex rather than medial temporal lobe. Neuropathologic studies provide consistent evidence of accelerated accumulation of hyperphosphorylated microtubule associated protein tau in AD + P. Finally, studies of familial aggregation of AD + P have established that the risk for psychosis in AD is, in part, genetically mediated. Although no genes are established as associated with AD + P, the first genome-wide association study of AD + P has generated some promising leads. The study of the neurobiology of AD + P is rapidly accelerating and may be poised for translational discovery. This process can be enhanced by identifying points of convergence and divergence with the neurobiology of AD proper and of schizophrenia, by innovative extension of current approaches, and by development of relevant animal models.
Behavioral disorders in dementia: Appropriate nondrug interventions and antipsychotic use
2016, American Family Physician
Citation Excerpt :
Approximately 15% to 75% of persons with dementia have delusions, delusional misidentifications, hallucinations (usually visual), wandering, agitation, aggression, and other psychotic behaviors.6
Behavioral and psychological symptoms of dementia pose management challenges for caregivers and clinicians. First-line nonpharmacologic treatments include eliminating physical and emotional stressors, modifying the patient's environment, and establishing daily routines. Family members and caregivers benefit from education about dementia symptoms and reminders that the behaviors are normal and unintentional. Cognitive and emotion-oriented interventions, sensory stimulation interventions, behavior management techniques, and other psychosocial interventions are modestly effective. In refractory cases, physicians may choose to prescribe off-label antipsychotics. Aripiprazole has the most consistent evidence of symptom improvement; however, this improvement is small. Olanzapine, quetiapine, and risperidone have inconsistent evidence of benefit. Physicians should use the smallest effective dose for the shortest possible duration to minimize adverse effects, most notably an increased mortality risk. Other adverse effects include anticholinergic and antidopaminergic effects, extrapyramidal symptoms, neuroleptic malignant syndrome, postural hypotension, metabolic syndrome, cardiac arrhythmia, and sedation. Patients should be monitored for these effects while receiving treatment; however, laboratory monitoring may be limited to patients receiving long-term therapy.
Sex and sleep disruption as contributing factors in Alzheimer's disease
2024, Handbook of Prevention and Alzheimer's Disease
Sex and Sleep Disruption as Contributing Factors in Alzheimer's Disease
2024, Journal of Alzheimer's Disease
Sex and Sleep Disruption as Contributing Factors in Alzheimer's Disease
2024, Advances in Alzheimer's Disease

View all citing articles on Scopus

^☆: Supported in part by NIA Grants AG03911 and AG05681.

View full text

Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type☆

Abstract

Psychiatr Clin North Am

About a peculiar disease of the cerebral cortex

Alz Dis Assoc Dis Orders

Changes of biogenic amines and their metabolites in post-mortem brains from patients with Alzheimer-type dementia

J Neurochem

Clinical Dementia Rating

Br J Psychiatry

Mild senile dementia of Alzheimer type: Research Diagnostic Criteria recruitment and description of a study population

J Neurol Neurosurg Psychiatry

Mild senile dementia of the Alzheimer type

Longitudinal assessment

The association between quantitative measures of dementia and of senile change in the cerebral gray matter of elderly subjects

Br J Psychiatry

Loss of neurons of origin of adrenergic projection of cerebral cortex (nucleus locus ceruleus) in senile dementia

Neurology

Symptoms of depression in senile dementia of the Alzheimer type

Alz Dis Assoc Dis

Serotonin receptor changes in dementia of the Alzheimer type

J Neurochem

Neuropsychiatrie aspects of multi-infarct dementia and dementia of the Alzheimer type

Arch Neurol

Recent advances in the neurochemistry of Alzheimer's disease

J Clin Psychiatry

Laminar organization of cholinergic circuits in human frontal cortex in Alzheimer's disease and aging

Neurology

Erotomania and senile dementia of the Alzheimer type

Br J Psychiatry

Neurochemical studies of early-onset Alzheimer's disease

N Engl J Med

Alzheimer's disease. A clinical-pathologic analysis of 23 cases with a theory on pathogenesis

J Nerv Ment Dis